tydes tirzepatide Lab Results Tirzepatide - Welcome

Physical activity, when appropriate for your health status, can improve both mood and energy levels

Tirzepatide (Zepbound for obesity, Mounjaro for type 2 diabetes) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist

The two FDA approved doses are 1.7mg per week and 2.4mg per week administered subcutaneously on designated days each week, either Monday or Thursday

Another study compared the weight loss effects of the highest doses of tirzepatide and semaglutide

Clinical trials show that patients using Ozempic (semaglutide) lose on average around 15% of their body weight over 1218 months (STEP 1 trial)